Insulin resistance and vascular disease

Simple item page
dc.contributor.authorMaritz F.J.
dc.contributor.authorMaritz F.J.
dc.date.accessioned2011-05-15T16:16:58Z
dc.date.accessioned2011-05-15T16:16:58Z
dc.date.available2011-05-15T16:16:58Z
dc.date.available2011-05-15T16:16:58Z
dc.date.issued2004
dc.date.issued2004
dc.description.abstractThe insulin resistance syndrome comprises a typical cluster of cardiovascular risk factors and is predicted to increase dramatically over the next few decades. The disease process starts many years before the condition is clinically obvious and targets primarily the cardiovascular system. The pathogenesis involves a complex interplay between all the associated cardiovascular risk factors but endothelial dysfunction plays a major role. Management of these patients involves management of all the associated risk factors and should be aimed primarily at early detection and the prevention of vascular morbidity and mortality in the short and long term.
dc.description.abstractThe insulin resistance syndrome comprises a typical cluster of cardiovascular risk factors and is predicted to increase dramatically over the next few decades. The disease process starts many years before the condition is clinically obvious and targets primarily the cardiovascular system. The pathogenesis involves a complex interplay between all the associated cardiovascular risk factors but endothelial dysfunction plays a major role. Management of these patients involves management of all the associated risk factors and should be aimed primarily at early detection and the prevention of vascular morbidity and mortality in the short and long term.
dc.description.versionArticle
dc.description.versionArticle
dc.identifier.citationJournal of Endocrinology, Metabolism and Diabetes of South Africa
dc.identifier.citation9
dc.identifier.citation2
dc.identifier.citationJournal of Endocrinology, Metabolism and Diabetes of South Africa
dc.identifier.citation9
dc.identifier.citation2
dc.identifier.issn16089677
dc.identifier.issn16089677
dc.identifier.urihttp://hdl.handle.net/10019.1/14013
dc.identifier.urihttp://hdl.handle.net/10019.1/14013
dc.subjectalbumin; dipeptidyl carboxypeptidase inhibitor; fibric acid derivative; glucose; homocysteine; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; low density lipoprotein cholesterol; metformin; oral antidiabetic agent; peroxisome proliferator activated receptor alpha; peroxisome proliferator activated receptor gamma; pioglitazone; placebo; plasminogen activator inhibitor 1; proteinase inhibitor; ramipril; rosiglitazone; article; atherosclerosis; behavior modification; cardiovascular risk; cardiovascular system; clinical trial; coronary artery disease; diabetic angiopathy; diagnostic accuracy; disease course; dyslipidemia; early diagnosis; endothelium cell; exercise; human; hyperglycemia; hyperhomocysteinemia; impaired glucose tolerance; insulin resistance; lifestyle; metabolic syndrome X; microalbuminuria; morbidity; mortality; non insulin dependent diabetes mellitus; pathogenesis; patient compliance; prediction; primary prevention; rhabdomyolysis; risk factor; smoking cessation; vascular disease
dc.subjectalbumin
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectfibric acid derivative
dc.subjectglucose
dc.subjecthomocysteine
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectinsulin
dc.subjectlow density lipoprotein cholesterol
dc.subjectmetformin
dc.subjectoral antidiabetic agent
dc.subjectperoxisome proliferator activated receptor alpha
dc.subjectperoxisome proliferator activated receptor gamma
dc.subjectpioglitazone
dc.subjectplacebo
dc.subjectplasminogen activator inhibitor 1
dc.subjectproteinase inhibitor
dc.subjectramipril
dc.subjectrosiglitazone
dc.subjectarticle
dc.subjectatherosclerosis
dc.subjectbehavior modification
dc.subjectcardiovascular risk
dc.subjectcardiovascular system
dc.subjectclinical trial
dc.subjectcoronary artery disease
dc.subjectdiabetic angiopathy
dc.subjectdiagnostic accuracy
dc.subjectdisease course
dc.subjectdyslipidemia
dc.subjectearly diagnosis
dc.subjectendothelium cell
dc.subjectexercise
dc.subjecthuman
dc.subjecthyperglycemia
dc.subjecthyperhomocysteinemia
dc.subjectimpaired glucose tolerance
dc.subjectinsulin resistance
dc.subjectlifestyle
dc.subjectmetabolic syndrome X
dc.subjectmicroalbuminuria
dc.subjectmorbidity
dc.subjectmortality
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectpathogenesis
dc.subjectpatient compliance
dc.subjectprediction
dc.subjectprimary prevention
dc.subjectrhabdomyolysis
dc.subjectrisk factor
dc.subjectsmoking cessation
dc.subjectvascular disease
dc.titleInsulin resistance and vascular disease
dc.titleInsulin resistance and vascular disease
dc.typeArticle
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications